Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 84 EV-to-EBITDA is -2.01 as of Aug. 03, 2026. GuruFocus rates HAWPF with a GF Score™ of 84/100 and a GF Value™ of $9.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 746 Drug Manufacturers companies, Haw Par ranks better than 99.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Haw Par's enterprise value is $-447.4 Mil.
Haw Par's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $222.7 Mil. Therefore, Haw Par's EV-to-EBITDA for today is -2.01.
The historical rank and industry rank for Haw Par's EV-to-EBITDA or its related term are showing as below:
HAWPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.19 Med: -2.41 Max: 6.8
Current: -1.95
During the past 13 years, the highest EV-to-EBITDA of Haw Par was 6.80. The lowest was -9.19. And the median was -2.41.
HAWPF's EV-to-EBITDA is ranked better than 99.46% of 746
companies
in the Drug Manufacturers industry
Industry Median: 13.015
vs HAWPF: -1.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Haw Par's share price for today is $12.575.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.933.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Haw Par's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Haw Par's EV-to-EBITDA falls into.
Haw Par's current Enterprise Value is $-447.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $222.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a EV-to-EBITDA of -2.01 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Haw Par. According to the industry distribution chart, Haw Par ranks #4 out of 746 companies in the Drug Manufacturers industry, placing it in the top 0.5%.
Is Haw Par's EV-to-EBITDA too high?
Haw Par's current EV-to-EBITDA is -2.01. Based on the distribution chart, Haw Par ranks #4 out of 746 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #4 out of 746 companies for EV-to-EBITDA. This places Haw Par in the top 1% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Haw Par. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current EV-to-EBITDA is -2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (HAWPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.28, compared to a current price of $12.58 — trading 35.5% above its estimated fair value. The current EV-to-EBITDA is -2.01. Haw Par's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Haw Par (HAWPF), the current EV-to-EBITDA is -2.01 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.58 is trading 35.5% above its estimated GF Value™ of $9.28.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for HAWPF:
EV-to-EBITDA: -2.01
GF Value™: $9.28 vs. price of $12.58 (35.5% above fair value)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
84GF Score
Get the complete analysis for HAWPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
